Company Performance - Organon (OGN) closed at $14.62, reflecting a -1.81% change from the previous day, underperforming compared to the S&P 500's daily loss of 0.95% [1] - The stock has decreased by 6.94% over the past month, contrasting with the Medical sector's gain of 5.16% and the S&P 500's gain of 1.86% [1] Earnings Forecast - Organon is expected to release its earnings on February 13, 2025, with projected earnings per share (EPS) of $0.86, indicating a 2.27% decrease from the same quarter last year [2] - The consensus estimate for quarterly revenue is $1.57 billion, down 2.03% from the previous year [2] Analyst Estimates - Recent changes to analyst estimates for Organon are crucial as they reflect short-term business trends and analysts' confidence in the company's performance [3] - A 2.27% decline in the Zacks Consensus EPS estimate has been noted over the past month, with Organon currently holding a Zacks Rank of 3 (Hold) [5] Valuation Metrics - Organon has a Forward P/E ratio of 3.7, significantly lower than the industry's average Forward P/E of 17.62, indicating a valuation discount [6] - The company has a PEG ratio of 0.78, compared to the Medical Services industry's average PEG ratio of 1.6 [6] Industry Context - The Medical Services industry, part of the Medical sector, holds a Zacks Industry Rank of 181, placing it in the bottom 28% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Group 1: Company Performance - Organon (OGN) closed at $15.97, reflecting a +0.82% increase, outperforming the S&P 500's gain of 0.53% [1] - Over the past month, Organon shares increased by 6.17%, surpassing the Medical sector's gain of 2.85% and the S&P 500's gain of 1.24% [1] Group 2: Upcoming Earnings Report - Organon is set to release its earnings report on February 13, 2025, with projected earnings per share (EPS) of $0.87, indicating a 1.14% decrease from the same quarter last year [2] - The consensus estimate for revenue is $1.57 billion, down 1.69% from the prior-year quarter [2] Group 3: Analyst Estimates and Stock Performance - Recent changes to analyst estimates for Organon are crucial for investors, as positive revisions indicate optimism about the company's outlook [3] - The Zacks Rank system, which reflects these estimate changes, provides actionable ratings for investors [4] Group 4: Zacks Rank and Valuation - Organon currently holds a Zacks Rank of 4 (Sell), with a 2.72% decrease in the consensus EPS estimate over the last 30 days [5] - The company has a Forward P/E ratio of 3.95, significantly lower than the industry average of 17.47, indicating it is trading at a discount [6] - Organon's PEG ratio is 0.83, compared to the Medical Services industry's average PEG ratio of 1.67 [6] Group 5: Industry Context - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 150, placing it in the bottom 41% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

Company Performance - Organon (OGN) closed at $16.26, with a gain of +1.82% from the previous trading session, outperforming the S&P 500's loss of 1.46% [1] - Over the past month, Organon shares increased by 6.04%, surpassing the Medical sector's gain of 1.84% and the S&P 500's gain of 1.08% [1] Upcoming Earnings - Organon's earnings report is scheduled for February 13, 2025, with projected earnings per share (EPS) of $0.87, reflecting a 1.14% decrease from the same quarter last year [2] - The consensus estimate for revenue is $1.57 billion, down 1.87% from the prior-year quarter [2] Analyst Estimates - Recent changes to analyst estimates for Organon are important as they reflect near-term business trends, with positive revisions indicating a favorable outlook on the company's health and profitability [3] - The Zacks Consensus EPS estimate has shifted 0.97% downward over the past month, resulting in a Zacks Rank of 4 (Sell) for Organon [5] Valuation Metrics - Organon is currently trading with a Forward P/E ratio of 3.93, significantly lower than the industry average of 17.43 [6] - The company has a PEG ratio of 0.83, compared to the Medical Services industry average PEG ratio of 1.56 [6] Industry Context - The Medical Services industry, part of the Medical sector, has a Zacks Industry Rank of 159, placing it in the bottom 37% of over 250 industries [7] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [7]

The most recent trading session ended with Organon (OGN) standing at $15.88, reflecting a +0.89% shift from the previouse trading day's closing. The stock's performance was ahead of the S&P 500's daily gain of 0.88%. Elsewhere, the Dow gained 1.24%, while the tech-heavy Nasdaq added 0.65%.Prior to today's trading, shares of the pharmaceutical company had gained 7.07% over the past month. This has outpaced the Medical sector's loss of 0.32% and the S&P 500's gain of 1.17% in that time.Analysts and investors ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.I have been tracking the progress of Organon (NYSE: OGN ), spun out of Pharma giant Merck ( MRK ), ever since it first began trading as a separate entity back in MayThe gro ...

Key Points Company and Industry 1. **Company**: Organon & Co. (NYSE:OGN) 2. **Industry**: Healthcare, specifically pharmaceuticals and biotechnology 3. **Event**: JPMorgan Annual Healthcare Conference Call 4. **Date**: January 13, 2025 5. **Time**: 6:45 PM ET Core Views and Arguments 1. **Solid 2024 Performance**: CEO Kevin Ali highlights a strong 2024, particularly growth in Nexplanon, the company's core product, with a 15% increase in sales both domestically and internationally [5]. 2. **Nexplanon Growth**: Nexplanon's sales growth is attributed to its strong performance, with a significant increase in the third quarter of 2024 [5]. 3. **Emgality Deal**: Organon's partnership with Lilly on Emgality is expected to generate approximately $100 million in revenue for the year 2024, with potential for expansion into additional territories, including emerging markets [5]. Other Important Content 1. **Management Team**: The call features CEO Kevin Ali and CFO Matt Walsh from Organon & Co. [1]. 2. **Conference Participants**: The call is hosted by Chris Schott from JPMorgan [1]. 3. **Focus on 2025**: The conversation primarily focuses on Organon's business outlook and performance in 2024, with a forward-looking perspective towards 2025 [4].

The latest trading session saw Organon (OGN) ending at $15.06, denoting a +0.74% adjustment from its last day's close. The stock outpaced the S&P 500's daily loss of 1.11%. Elsewhere, the Dow lost 0.77%, while the tech-heavy Nasdaq lost 1.49%.The pharmaceutical company's shares have seen a decrease of 6.45% over the last month, not keeping up with the Medical sector's loss of 4.56% and the S&P 500's gain of 0.4%.Market participants will be closely following the financial results of Organon in its upcoming r ...

Group 1 - The article discusses the author's long positions in several pharmaceutical companies, including ABBV, MRK, AMGN, JNJ, and RHHBF, indicating a positive outlook on these stocks [1] - There is a mention of a potential long position in Organon & Co. within the next 72 hours, suggesting an interest in this stock as well [2] Group 2 - The article emphasizes that past performance is not indicative of future results, highlighting the inherent uncertainty in investment outcomes [3] - It clarifies that no specific investment recommendations are provided, and the views expressed may not represent the broader platform's stance [3]

Table of Contents Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ Form 10-Q ________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For ...

Core Insights - Organon reported revenue of $1.58 billion for the quarter ended September 2024, reflecting a 4.2% increase year-over-year and surpassing the Zacks Consensus Estimate of $1.56 billion by 1.37% [1] - The company's EPS was $0.87, consistent with the same quarter last year, and exceeded the consensus EPS estimate of $0.85 by 2.35% [1] Revenue Performance - Women's Health revenue from Nexplanon/Implanon NXT in the U.S. was $172 million, exceeding the estimated $164.46 million, marking a 17.8% increase year-over-year [3] - U.S. geographic revenue was $398 million, slightly below the estimated $400.64 million, with a year-over-year increase of 7.6% [3] - Revenue from Women's Health NuvaRing was $7 million, significantly lower than the estimated $10.08 million, representing a 61.1% decrease year-over-year [3] - Revenue from Women's Health Follistim AQ was $26 million, slightly above the estimated $25.52 million, with an 18.2% year-over-year increase [3] - Total revenue from Women's Health was $440 million, below the estimated $452.30 million, reflecting a 5.3% increase year-over-year [3] - Total revenue from Biosimilars was $165 million, slightly below the estimated $168.58 million, with a year-over-year increase of 16.2% [3] Stock Performance - Over the past month, Organon shares have returned -3.5%, contrasting with the Zacks S&P 500 composite's +1% change [4] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [4]